Nasus Pharma Announces Publication Of Its Positive Clinical Results With FMXIN002 Intranasal Powder Epinephrine Spray In The Journal Of Allergy And Clinical Immunology In Practice
(Adnkronos) – Rapid and higher epinephrine absorption – for potentially quicker rescue of patients in anaphylactic shock TEL AVIV, Israel, Aug. 8, 2023 /PRNewswire/ — Nasus Pharma Ltd a clinical-stage biopharmaceutical company
